<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304118</url>
  </required_header>
  <id_info>
    <org_study_id>registry_98118</org_study_id>
    <nct_id>NCT04304118</nct_id>
  </id_info>
  <brief_title>Rajaie Cardiomyopathy and Myocarditis Registry</brief_title>
  <official_title>Rajaie Cardiomyopathy and Myocarditis Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajaie Cardiovascular Medical and Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajaie Cardiovascular Medical and Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of patients with cardiomyopathies who referred to Rajaei Cardiovascular
      medical and research center is remarkable, and also the mission of this center is to achieve
      center of excellence in the field of cardiomyopathy. Rajaie Cardiomyopathy and myocarditis
      Registry study is an observational registry of consecutive patients with four cardiomyopathy
      subtypes: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic
      right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM) as well as
      myocarditis designed to determine clinical characteristics, natural history, current
      therapeutic approaches, response to treatment and long-term outcomes of patients with
      cardiomyopathy and myocarditis and to address limitations in extant evidence to improve
      prognostication in cardiomyopathies and myocarditis. Prediction of mortality and response to
      different treatments in these patients using artificial intelligence is another aim of this
      registry
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">November 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Admissions to hospital</measure>
    <time_frame>1 year</time_frame>
    <description>Number of hospitalizations for cardiovascular reasons</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of chronic heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>significant decrease in left ventricular ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Stroke/Transient ischemic attack</measure>
    <time_frame>1 year</time_frame>
    <description>At least 80% CT/MRI verification of the diagnosis of ischemic stroke/Transient ischemic attack, within the first week of stroke onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of sudden death</measure>
    <time_frame>1 year</time_frame>
    <description>unexpected death from a cardiovascular cause in a person with or without preexisting heart disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of heart trasplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac transplantation in patients with end-stage HF who remain symptomatic despite optimal medical therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response to current therapeutic approaches</measure>
    <time_frame>1 year</time_frame>
    <description>Implantable cardioverter defibrillator implantation, Cardiac resynchronisation therapy, septal myectomy, ablation, cardiac transplantation and medications</description>
  </secondary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Clinical Characteristics</condition>
  <condition>Natural History</condition>
  <condition>Long-term Outcomes</condition>
  <condition>Current Therapeutic Approaches</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with documented cardiomyopathy/ myocarditis fulfilling standard diagnostic
        criteria based on the ESC guideline for cardiomyopathy/ myocarditis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age greater than one year

          2. documented cardiomyopathy/ myocarditis fulfilling standard diagnostic criteria

          3. able to give informed consent or in the case of child consent from a parent

        Exclusion Criteria:

        Patients who have not consent to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Behshid Ghadrdoost, PhD</last_name>
    <phone>+982123923017</phone>
    <email>behshid.ghadrdoost@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Behshid Ghadrdoost</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Behshid Ghadrdoost, PhD</last_name>
      <phone>+982123923017</phone>
      <email>behshid.ghadrdoost@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 7, 2020</last_update_submitted>
  <last_update_submitted_qc>March 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

